Skip to main content

Table 4 Quantitative measures of left ventricular function

From: Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial

Variable Placebo (95 % CI) WJMSCs(95 % CI) P value
(number = 55) (number = 57)
Global LVEF (%)    
Baseline    
 Mean 51.0±1.1(48.8~53.3) 52.1±1.0(50.2~54.1) 0.46
4 Months    
 Mean 54.2±0.9(52.5~56.1) 58.5±0.7(57.1~60.0) 0.0003
 Difference 3.2±0.9(1.4~5.0) 6.4±0.7(4.9~7.9) 0.008
 P value (baseline vs.6 months) 0.0009 <0.0001  
12 Months    
 Mean 54.5±0.8(52.8~56.2) 58.8±0.8(57.3~60.4) 0.0002
 Difference 3.5±0.8(1.9~5.0) 6.7±0.8(5.1~8.3) 0.004
 P value (baseline vs.12 months) <0.0001 <0.0001  
18 Months    
 Mean 54.0±0.8( 52.3~55.7) 60.0±0.5 (58.9~61.0) <0.0001
 Difference 2.8±1.2(0.4~5.1) 7.8±0.9(6.0~9.7) 0.001
 P value (baseline vs.18 months) 0.05 <0.0001  
LVFS (%)    
Baseline    
 Mean 26.6±0.7(25.2~27.9) 27.3±0.6(26.0~28.6) 0.42
4 Months    
 Mean 29.7±0.7(28.3~31.0) 32.6±0.6(31.4~33.9) 0.002
 Difference 3.1±0.6(1.9~4.3) 5.3±0.6(4.0~6.6) 0.01
 P value (baseline vs.6 months) <0.0001 <0.0001  
12 Months    
 Mean 29.8±0.6(28.5~31.0) 32.7±0.5(31.7~33.8) 0.0005
 Difference 3.2±0.5(2.1~4.3) 5.4±0.5(4.3~6.5) 0.005
 P value (baseline vs.12 months) <0.0001 <0.0001  
18 Months    
 Mean 28.6±0.6(20.8~35.6) 33.6±0.5(27.3~39.1) <0.0001
 Difference 2.1±0.8(−8.9~13.5) 6.2±0.7(−4.1~16.4) <0.0001
 P value (baseline vs.18 months) 0.01 <0.0001  
WMSI (17-segment model)    
Baseline    
 Mean 1.28±0.03(1.23~1.34) 1.29±0.03(1.24~1.34) 0.76
4 Months    
 Mean 1.16±0.02(1.11~1.21) 1.10±0.01(1.07~1.12) 0.02
 Difference −0.12±0.02(−0.16~−0.09) −0.19±0.02(−0.23~−0.16) 0.003
 P value (baseline vs.6 months) <0.0001 <0.0001  
12 Months    
 Mean 1.15±0.02(1.11~1.20) 1.09±0.02(1.06~1.12) 0.02
 Difference −0.13±0.02( −0.17~−0.10) −0.20±0.02(−0.23~−0.17) 0.003
 P value (baseline vs.12 months) <0.0001 <0.0001  
18 Months    
 Mean 1.16±0.9(1.02~1.40) 1.07±0.01(1.00~1.17) <0.0001
 Difference −0.13±0.02(−0.42~0.08) −0.22±0.02(−0.57~0.04) 0.01
 P value (baseline vs.18 months) <0.0001 <0.0001  
End-systolic volume (ml)    
Baseline    
 Mean 66.0±3.1(59.8~72.2) 63.1±2.8(57.5~68.7) 0.38
4 Months    
 Mean 63.4±2.8(57.7~69.0) 55.9±2.1(51.7~60.2) 0.07
 Difference −2.6±1.8(−6.4~1.1) −7.2±1.9(−10.9~−3.5) 0.09
 P value (baseline vs.6 months) 0.16 0.0003  
12 Months    
 Mean 62.5±2.8(56.9~68.0) 55.1±2.1(50.9~59.4) 0.06
 Difference −3.5±1.9(−7.3~0.2) −8.0±2.0(−12.1~−3.9) 0.12
 P value (baseline vs.12 months) 0.11 0.0002  
18 Months    
 Mean 62.8±0.9(59.1~66.6) 49.2±1.0(47.1~51.2) <0.0001
 Difference −2. 9±2.1(−7.1~1.3) −14.0±2.2(−18.4~−9.5) 0.0004
 P value (baseline vs.18 months) 0.2 <0.0001  
End-diastolic volume (ml)    
Baseline    
 Mean 132.2±3.9(124.3~140.0) 130.3±3.8(122.7~137.9) 0.49
4 Months    
 Mean 136.0±4.0(127.9~144.0) 133.2±3.2(126.8~139.5) 0.72
 Difference 3.8±2.3(−0.7~8.4) 2.9±2.6(−2.3~8.0) 0.78
 P value (baseline vs.6 months) 0.20 0.07  
12 Months    
 Mean 134.5±3.9(126.6~142.4) 131.9±3.1(125.8~138.1) 0.60
 Difference 2.4±2.5(−2.6~7.3) 1.6±2.8(−4.0~7.2) 0.84
 P value (baseline vs.12 months) 0.45 0.22  
18 Months    
 Mean 136.4±3.1(130.1~142.7) 122.7±1.6 (119.5~125.8) 0.0001
 Difference 4.1±2.4(−0.8~9.0) −7.6±3.13(−13.9~−1.4) 0.004
 P value (baseline vs.18 months) 0.1 <0.0001  
  1. LVEF, LVESV and LVEDV by two dimensional-ECG from baseline to 18 months post-treatment between the WJMSC group and placebo-control group were analyzed by ANCOVA. Treatment effects are expressed as differences in least-squares means (ANCOVA model) with 95 % CI ANCOVA analysis of covariance, CI confidence interval, ECG echocardiogram, LVEDV left ventricular end-diastolic volume, LVESF left ventricular end-systolic volume, WJMSC Wharton’s jelly-derived mesenchymal stem cells